Cullinan Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $CGEM in the last 7 days.
No SEC Form 4 filings for $CGEM in the last 30 days.
See all $CGEM insider activity →Cullinan Therapeutics (CGEM) dosed the first patient in a Phase 2 study of CLN-049, a treatment for relapsed/refractory AML. The study aims to evaluate the drug's safety and efficacy, with updates expected in December. CLN-049 has received Orphan Drug and Fast Track designations from the FDA.
Analysts maintained Buy ratings on Monte Rosa Therapeutics (GLUE) and Cullinan Management (CGEM). GLUE has a $28.17 avg. price target (147.1% upside), while CGEM has a $35.70 target (141.9% upside). Both have Strong Buy consensus.
H.C. Wainwright reiterated a Buy rating and $35 price target for Cullinan Oncology (CGEM) after its rolling NDA submission for zipalertinib. The stock is up 153% over a year, trading at $14.53. Positive Phase 3 trial results showed improved outcomes for zipalertinib plus chemotherapy in NSCLC. Approval could trigger milestone payments. CGEM has strong cash position but high annual burn rate.
Recent CGEM coverage spans financial news, regulation and technology.
The start of a pivotal Phase 2 trial reduces development risk and may lift sentiment toward CGEM.
Reiterated Buy rating could sustain or modestly boost the stock.
Analyst rating reinforcement and NDA filing suggest potential FDA approval, likely driving the stock higher.
HC Wainwright reiterated a Buy rating on Cullinan Therapeutics with a $35 price target, implying 140.9% upside from the Oct 1 close. The firm cited strong clinical data for zipalertinib, including a 65% overall response rate, and potential milestone payments of $100 million upon approval.
The NDA filing signals progress toward potential FDA approval, likely prompting buying interest.
AlphAI scores every news story that mentions CGEM with an AI model for sentiment and relevance, and aggregates insider trades from Cullinan Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cullinan Therapeutics (CGEM) dosed the first patient in a Phase 2 study of CLN-049, a treatment for relapsed/refractory AML. The study aims to evaluate the drug's safety and efficacy, with updates expected in December. CLN-049 has received Orphan Drug and Fast Track designations from the FDA.
2 min readAnalysts maintained Buy ratings on Monte Rosa Therapeutics (GLUE) and Cullinan Management (CGEM). GLUE has a $28.17 avg. price target (147.1% upside), while CGEM has a $35.70 target (141.9% upside). Both have Strong Buy consensus.
1 min readH.C. Wainwright reiterated a Buy rating and $35 price target for Cullinan Oncology (CGEM) after its rolling NDA submission for zipalertinib. The stock is up 153% over a year, trading at $14.53. Positive Phase 3 trial results showed improved outcomes for zipalertinib plus chemotherapy in NSCLC. Approval could trigger milestone payments. CGEM has strong cash position but high annual burn rate.
3 min readHC Wainwright reiterated a Buy rating on Cullinan Therapeutics with a $35 price target, implying 140.9% upside from the Oct 1 close. The firm cited strong clinical data for zipalertinib, including a 65% overall response rate, and potential milestone payments of $100 million upon approval.
1 min readCullinan Therapeutics (CGEM) initiated an FDA filing for zipalertinib, a lung cancer drug, in combination with chemotherapy. The Phase 3 trial met its primary endpoint, showing improved progression-free survival. The company expects to complete the NDA submission by year-end 2026 and could receive $130 million in milestones upon approvals. Zipalertinib is being developed with Taiho Oncology and Taiho Pharmaceutical.
2 min readCullinan Therapeutics (CGEM) initiated NDA submission for zipalertinib plus chemotherapy in first-line EGFR exon20ins NSCLC under FDA's RTOR program, with completion expected by year-end 2026. The submission follows positive Phase 3 REZILIENT3 trial results, showing significant improvement in progression-free survival. Zipalertinib has FDA Breakthrough Therapy designation, and Cullinan may receive $100M in milestone payments upon approval.
2 min readCullinan Therapeutics (CGEM) shares fell 5% after delaying rheumatoid arthritis data to December, later than expected. The company also faces safety concerns about zipalertinib. Cullinan plans to present data on other drugs at upcoming conferences. TD Cowen maintains a Buy rating, citing potential catalysts. CGEM stock is up 55% year-to-date.
2 min readCullinan Therapeutics (CGEM) announced Q4 2026 milestones for its T cell engager pipeline. Key updates include velinotamig data in November, CLN-978 and CLN-049 updates in December. The company is developing treatments for autoimmune diseases and AML. CGEM's stock closed at $16.87, down 22.15%.
2 min readCullinan Therapeutics, Inc. (CGEM) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and
1 min readCullinan Therapeutics (CGEM) reported Phase 3 REZILIENT3 results, showing zipalertinib plus chemotherapy achieved 14.5 months median PFS vs. 8.5 months for chemotherapy alone in NSCLC patients. While efficacy is promising, high adverse event rates raise toxicity concerns. The company shares U.S. profits with Taiho Pharmaceutical.
3 min read
